ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer (ADELE): a randomised phase 2 trial

Primary Sponsor

ANZGOG

Collaborating Groups

TROG Cancer Research

Participating Centres

Current Accrual

Trial Chairperson

Professor Linda Mileshkin, Peter MacCallum Cancer Centre
Dr Yeh Chen Lee, NHMRC Clinical Trials Centre & Prince of Wales Hospital

Trial Contact

qa@trog.com.au

Related Post

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a

June 15, 2021

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery

Ductal carcinoma in situ (DCIS) of the breast is

Skip to toolbar